NDC 63323-322-41 - Imipenem and Cilastatin
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 63323-322
- Requested NDC
- 63323-322-41
- Package NDCs from labels
- 63323-322-21, 63323-322-93, 63323-322-41, 63323-322-94, 63323-322-01, 63323-322-25
- Manufacturer
- Fresenius Kabi USA, LLC | ACS Dobfar S.p.A. | Zambon Switzerland Ltd
- Effective date
- 2022-10-11
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| IMIPENEM - Fresenius Kabi USA, LLC | ACS Dobfar S.p.A. | Zambon Switzerland Ltd | Fresenius Kabi USA, LLC | ACS Dobfar S.p.A. | Zambon Switzerland Ltd | 2022-10-11 | HUMAN PRESCRIPTION DRUG LABEL |
| IMIPENEM - Fresenius Kabi USA, LLC | ACS Dobfar S.p.A. | Zambon Switzerland Ltd | Fresenius Kabi USA, LLC | ACS Dobfar S.p.A. | Zambon Switzerland Ltd | 2022-10-10 | HUMAN PRESCRIPTION DRUG LABEL |
| IMIPENEM - Fresenius Kabi USA, LLC | ACS Dobfar S.p.A. | Zambon Switzerland Ltd | Fresenius Kabi USA, LLC | ACS Dobfar S.p.A. | Zambon Switzerland Ltd | 2022-10-06 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 63323-322-01 | Imipenem and Cilastatin | 20 mL in 1 VIAL, SINGLE-DOSE | INJECTION, POWDER, FOR SOLUTION | 20 | 12 | |
| 63323-322-25 | Imipenem and Cilastatin | 25 in 1 CARTON | INJECTION, POWDER, FOR SOLUTION | 25 | 12 | |
| 63323-322-41 | Imipenem and Cilastatin | 20 mL in 1 VIAL, SINGLE-DOSE | INJECTION, POWDER, FOR SOLUTION | 20 | 7 | |
| 63323-322-94 | Imipenem and Cilastatin | 25 in 1 CARTON | INJECTION, POWDER, FOR SOLUTION | 25 | 7 | |
| 63323-322-21 | Imipenem and Cilastatin | 20 mL in 1 VIAL, SINGLE-DOSE | INJECTION, POWDER, FOR SOLUTION | 20 | 5 | |
| 63323-322-93 | Imipenem and Cilastatin | 25 in 1 CARTON | INJECTION, POWDER, FOR SOLUTION | 25 | 5 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 63323-322 | IMIPENEM AND CILASTATIN (IMIPENEM AND CILASTATIN SODIUM) INJECTION, POWDER, FOR SOLUTION [FRESENIUS KABI USA, LLC] | 12 | Current NDC, Legacy NDC, 2 package rows | 20221020_6ab0ca9e-9a79-4cab-9f09-470eda06952e.zip |
| 63323-322 | IMIPENEM AND CILASTATIN (IMIPENEM AND CILASTATIN SODIUM) INJECTION, POWDER, FOR SOLUTION IMIPENEM AND CILASTATIN (IMIPENEM AND CILASTATIN SODIUM) INJECTION, POWDER, FOR SOLUTION [FRESENIUS KABI USA, LLC] | 7 | Current NDC, Legacy NDC, 2 package rows | 20221027_0a1dd9b9-ada1-4bff-9dcb-18961254e9e8.zip |
| 63323-322 | IMIPENEM AND CILASTATIN (IMIPENEM AND CILASTATIN SODIUM) INJECTION, POWDER, FOR SOLUTION IMIPENEM AND CILASTATIN (IMIPENEM AND CILASTATIN SODIUM) INJECTION, POWDER, FOR SOLUTION [FRESENIUS KABI USA, LLC] | 5 | Current NDC, Legacy NDC, 2 package rows | 20221103_ce771566-c4f2-447e-944a-6b908925c90b.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 63323-322-01 | EA - Each | 63323-322 | 34deeaf8-735f-4d5d-8ce0-f7bca735d05f | 1 | 2022-01-06 |
| 63323-322-20 | EA - Each | 63323-322 | 15d13752-d665-47b7-a49c-deac99c4cf15 | 1 | 2012-07-24 |
| 63323-322-21 | EA - Each | 63323-322 | f295eda5-5f73-456c-93a6-9c36771eb017 | 1 | 2022-04-06 |
| 63323-322-25 | EA - Each | 63323-322 | 3224fb37-f888-4ac9-943f-4fd3d043976d | 1 | 2013-02-13 |
| 63323-322-41 | EA - Each | 63323-322 | 1036c74b-ed3a-40f7-bbf1-87d3249cda17 | 1 | 2022-10-06 |
| 63323-322-93 | EA - Each | 63323-322 | 09ffc170-6c97-4df2-939c-49e83a8a41f7 | 1 | 2016-07-19 |
| 63323-322-94 | EA - Each | 63323-322 | 89f6cade-0bdd-4c18-b4ce-d0e9ff9c7655 | 1 | 2015-01-05 |
DailyMed Socrata Ingredients#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Drug Mart Effervescent Pain Relief | ASPIRIN, CITRIC ACID, SODIUM BICARBONATE | Discount Drug Mart, Inc | 8bc65603-1dbf-30ab-e053-2995a90a7c15 | 2024-11-13 | Warnings | 8MDF5V39QO |
| Best Choice Effervescent Antacid Pain Relief | ASPIRIN, CITRIC ACID, SODIUM BICARBONATE | Valu Merchandisers Company | 8aab905b-5fe7-dddb-e053-2995a90a6c6f | 2024-11-13 | Warnings | 8MDF5V39QO |
| Publix Fast Relief Effervescent | ASPIRIN, CITRIC ACID, SODIUM BICARBONATE | Publix Super Markets Inc. | 73051f16-2569-7394-e053-2991aa0a5359 | 2024-11-13 | Warnings | 8MDF5V39QO |
| Quality Choice Effervescent Antacid and Pain Relief | ASPIRIN, CITRIC ACID, SODIUM BICARBONATE | Chain Drug Marketing Association | 70d265de-ff94-e0e4-e053-2a91aa0a962a | 2024-11-13 | Warnings | 8MDF5V39QO |
| Quality Choice Extra Strength Effervescent Antacid and Pain Relief | ASPIRIN, ANHYDROUS CITRIC ACID, SODIUM BICARBONATE | Chain Drug Marketing Association | 9f7d0c96-a561-a8a0-e053-2995a90a250b | 2024-11-13 | Warnings | 8MDF5V39QO |
| WinCo Foods Effervescent Antacid and Pain Relief | ASPIRIN, SODIUM BICARBONATE, CITRIC ACID TABLET | WinCo Foods, LLC | 0c8a755a-089f-477f-97e9-0dd6fdfbe99d | 2024-11-13 | Warnings | 8MDF5V39QO |
| Sodium Bicarbonate | SODIUM BICARBONATE | Rising Pharma Holdings, Inc. | f5a90c33-f29d-4d4b-b5e6-0b3c2514ce3e | 2024-11-01 | Boxed warning, Warnings | 8MDF5V39QO |
| Omeprazole and Sodium Bicarbonate | OMEPRAZOLE AND SODIUM BICARBONATE | ScieGen Pharmaceuticals, Inc. | a107804e-b308-4e79-9447-07d93016f70f | 2024-10-24 | Warnings, Adverse reactions | 8MDF5V39QO |
| OHTAS ISAN ANTACID | CALCIUM CARBONATE, SODIUM BICARBONATE | OHTA'S ISAN CO.,LTD. | 53380470-5748-6fa7-548e-7484ef204c0f | 2024-10-21 | Warnings | 8MDF5V39QO |
| OHTAS ISAN ANTACID | CALCIUM CARBONATE, SODIUM BICARBONATE | OHTA'S ISAN CO.,LTD. | 8723fe90-8402-4511-b6c6-b71cf98513e3 | 2024-10-21 | Warnings | 8MDF5V39QO |
| Elliotts B | SODIUM CATION, SODIUM BICARBONATE, ANHYDROUS DEXTROSE, MAGNESIUM SULFATE, POTASSIUM CHLORIDE, CALCIUM CHLORIDE, SODIUM PHOSPHATE | Lukare Medical, LLC | 08036dbd-55b3-47b9-9890-000f253544f3 | 2024-10-16 | Warnings, Adverse reactions | 8MDF5V39QO |
| SODIUM BICARBONATE | SODIUM BICARBONATE INJECTION, | Long Grove Pharmaceuticals, LLC | a26d709b-b294-4b02-9a88-7e840f099a33 | 2024-09-25 | Warnings, Adverse reactions | 8MDF5V39QO |
| Insect sting relief latex 01 | SODIUM BICARBONATE | Cosmuses Cosmetics (Ningbo) Co., Ltd. | 1b9e2d4c-bc0c-6ed0-e063-6294a90a9103 | 2024-08-19 | Warnings | 8MDF5V39QO |
| Quality Choice Effervescent Antacid and Pain Relief - Extra Strength | ASPIRIN, ANHYDROUS CITRIC ACID, SODIUM BICARBONATE | Chain Drug Marketing Association | 1f926637-a61c-8eb7-e063-6394a90a6502 | 2024-08-13 | Warnings | 8MDF5V39QO |
| Omeprazole/Sodiium Bicarbonate | OMEPRAZOLE/SODIIUM BICARBONATE | Direct_rx | 1f7f63c1-17c2-9a05-e063-6394a90abc6f | 2024-08-12 | Warnings, Adverse reactions | 8MDF5V39QO |
| Omeprazole and Sodium Bicarbonate | OMEPRAZOLE AND SODIUM BICARBONATE | Dr. Reddy's Laboratories Inc., | ddee28fb-c871-a6d4-984f-515522b28412 | 2024-07-15 | Warnings | 8MDF5V39QO |
| PRIMAXIN IV | IMIPENEM AND CILASTATIN SODIUM | Merck Sharp & Dohme LLC | f41d8abd-7792-4918-1b93-bd83ea01955e | 2024-07-05 | Warnings, Adverse reactions | 1726204 71OTZ9ZE0A 5428WXZ74M |
| Insect sting relief pad 01 | SODIUM BICARBONATE | Cosmuses Cosmetics (Ningbo) Co., Ltd. | 1b0f0088-6482-6de7-e063-6294a90aeeb7 | 2024-06-17 | Warnings | 8MDF5V39QO |
| Omeprazole and Sodium Bicarbonate | OMEPRAZOLE AND SODIUM BICARBONATE | ANI Pharmaceuticals, Inc. | 63c3bd6c-a586-4ec0-8f45-ed936936dfeb | 2024-06-06 | Warnings, Adverse reactions | 8MDF5V39QO |
| Sodium Bicarbonate | SODIUM BICARBONATE | Steriscience Specialties Private Limited | eb2996b4-c04c-4678-b8a9-5cbbe509bb70 | 2024-03-04 | Warnings, Adverse reactions | 8MDF5V39QO |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.